Solventum Corporation

NYSE:SOLV 주식 리포트

시가총액: US$13.2b

Solventum 향후 성장

Future 기준 점검 1/6

Solventum 의 수익은 연간 5.3% 감소할 것으로 예상되는 반면, 연간 수익은 2.7% 로 증가할 것으로 예상됩니다. EPS는 연간 3.5% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 25.8% 로 예상됩니다.

핵심 정보

-5.3%

이익 성장률

-3.51%

EPS 성장률

Medical Equipment 이익 성장16.1%
매출 성장률2.7%
향후 자기자본이익률25.82%
애널리스트 커버리지

Good

마지막 업데이트27 May 2026

최근 향후 성장 업데이트

Recent updates

분석 기사 • May 13

Solventum's (NYSE:SOLV) Solid Earnings May Rest On Weak Foundations

The market for Solventum Corporation's ( NYSE:SOLV ) stock was strong after it released a healthy earnings report last...
내러티브 업데이트 • Apr 29

SOLV: 2026 Capital Allocation And Margin Discipline Will Support P/E Re Rating

The analyst price target for Solventum has been trimmed by about $1, reflecting recent cuts to Street targets and updated assumptions for slightly lower revenue, a modestly higher profit margin, and a small adjustment to future P/E expectations. Analyst Commentary Recent Street research on Solventum reflects a mix of optimism and caution, with several firms revising price targets and one new initiation with a bearish stance.
내러티브 업데이트 • Apr 15

SOLV: 2026 Capital Allocation And Margin Execution Will Support Multiple Expansion

The analyst price target for Solventum has been trimmed by about $5, as analysts factor in more conservative profit margin assumptions and slightly higher required returns, despite mixed recent rating changes on the stock. Analyst Commentary Recent Street research on Solventum reflects a mix of optimism and caution, with target changes and rating shifts clustered around the latest earnings update and subsequent model revisions.
Seeking Alpha • Apr 08

Solventum: A Hidden Breakup Story In Healthcare

Summary Solventum has a few good businesses, but the market is treating it as a complicated company. Its main parts are MedSurg, Dental, HIS, and a smaller Water / All Other. The thesis says the stock looks much cheaper than the value of the parts. The business could be worth about $166.6 per share based on SOTP analysis. The main idea is to keep MedSurg as the core business and see more value in the other parts on their own. Even in a portfolio simplification case, followed by Operational Margin increase, the shares could surge to as high as $186 per share. Read the full article on Seeking Alpha
내러티브 업데이트 • Mar 22

SOLV: 2026 Capital Allocation And Medtech Positioning Will Support Multiple Expansion

Analysts have modestly raised Solventum's implied price target to about $90.17, with recent research citing updated models after Q4 earnings, a series of upgrades, and adjusted assumptions for the discount rate and future P/E as key drivers of the change. Analyst Commentary Recent Street research around Solventum centers on refreshed models after Q4 earnings, a series of rating changes, and a wide range of price targets that cluster around the low to mid double digits.
내러티브 업데이트 • Mar 07

SOLV: 2026 Medtech Positioning And Capital Allocation Agenda Will Drive Future Upside

The analyst price target for Solventum has been adjusted from $89.25 to about $90.17, reflecting updated models after recent earnings and a series of supporting revisions from multiple firms that now view it as one of their preferred MedTech ideas heading into 2026. Analyst Commentary Recent research updates on Solventum cluster around revised models after earnings and a reset of expectations for large cap MedTech into 2026, with several firms adjusting price targets and ratings as they refine their views on valuation and execution risk.
내러티브 업데이트 • Feb 21

SOLV: 2026 Medtech Setup And Top-Idea Status Will Drive Future Upside

Solventum's analyst price targets have moved modestly higher toward $105, with analysts pointing to a more constructive medtech setup into 2026 and highlighting the stock as one of their preferred large cap ideas following recent upgrades at several firms. Analyst Commentary Recent research has focused on how Solventum fits into a broader large cap medtech group, with several firms adjusting targets and ratings as they refine expectations into 2026.
내러티브 업데이트 • Feb 06

SOLV: Top-Idea Status And Buybacks Will Support Future Upside Potential

Analysts have nudged their price target on Solventum higher, with the fair value estimate moving from about $88.55 to $89.25. This change reflects updated expectations for slightly faster revenue growth and modestly higher future P/E multiples following recent upgrades and more constructive views on large cap MedTech coverage.
내러티브 업데이트 • Jan 21

SOLV: MedTech Top-Idea Status And Buybacks Will Support Gradual Upside

Analysts have lifted their price target on Solventum from about $85.64 to roughly $88.55, citing updated expectations for revenue growth, a slightly higher future P/E and recent bullish research that highlights the company as a top MedTech idea. Analyst Commentary Recent research coverage on Solventum has leaned constructive, with several reports treating the stock as a key MedTech idea and adjusting price targets accordingly.
내러티브 업데이트 • Jan 06

SOLV: Wound Therapy Guidance And Buybacks Will Support Measured, Gradual Upside Ahead

Analysts now see Solventum’s fair value inching up from US$84.36 to US$85.64, reflecting small tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in their models. What's in the News Solventum announced updated consensus recommendations from an international panel of surgeons and wound care experts on the clinical use of closed incision negative pressure therapy (ciNPT) with reticulated open cell foam (ROCF) dressings, published in the International Wound Journal.
내러티브 업데이트 • Dec 13

SOLV: Portfolio Streamlining And Buybacks Will Support Balanced, Gradual Upside Ahead

Analysts have modestly raised their price target on Solventum, reflecting an updated fair value estimate of approximately $84.36 from about $82.80, as they factor in the impact of the company's P&F business sale and slightly improved long term valuation assumptions. Analyst Commentary Bullish Takeaways Bullish analysts view the P&F business sale as a cleaner portfolio move that supports a more focused operating model and clearer earnings trajectory.
분석 기사 • Dec 05

Solventum Corporation (NYSE:SOLV) Surges 26% Yet Its Low P/E Is No Reason For Excitement

Solventum Corporation ( NYSE:SOLV ) shares have had a really impressive month, gaining 26% after a shaky period...
내러티브 업데이트 • Nov 28

SOLV: Portfolio Changes And Share Buybacks Will Support Measured Improvement Ahead

Analysts have revised Solventum's price target slightly downward to $82.80 from $84.11. This change reflects updated expectations for revenue growth and profitability following recent strategic changes and portfolio reshaping initiatives.
내러티브 업데이트 • Nov 14

SOLV: Portfolio Reshaping And Sale Will Drive Momentum Into 2025

Analysts have revised Solventum's price target upward by $3 to $82. They cite recent portfolio changes as well as expectations for an improved cost structure and organic growth.
내러티브 업데이트 • Oct 31

SOLV: Portfolio Reshaping And Cost Controls Will Improve Outlook For 2025

Solventum's analyst price target has been raised by $3 to $82, as analysts point to recent portfolio reshaping and the sale of the P&F business as key factors that support an improved outlook. Analyst Commentary Recent analyst updates reflect a mix of positive developments and continued caution surrounding Solventum’s performance and outlook.
내러티브 업데이트 • Oct 17

Commercial Restructuring And New Product Launches Will Broaden International Reach

Solventum's analyst price target increased modestly to $82 from $79, as analysts point to the recent divestiture of its P&F business, along with ongoing improvements in its portfolio and cost structure, as key drivers for the update. Analyst Commentary Analyst sentiment on Solventum reflects a balance of cautious optimism and highlighted risks as the company navigates portfolio changes and future growth prospects.
내러티브 업데이트 • Oct 03

Commercial Restructuring And New Product Launches Will Broaden International Reach

Analysts have modestly lowered their average price target for Solventum by $1.60 to $85.11, citing recent portfolio reshaping and tempered profit margin expectations. Analyst Commentary Recent analyst research reflects a mix of optimism and caution regarding Solventum's future valuation and growth trajectory.
내러티브 업데이트 • Sep 04

Commercial Restructuring And New Product Launches Will Broaden International Reach

As there were no material changes in Solventum’s revenue growth or net profit margin forecasts, the consensus analyst price target remains unchanged at $86.71. What's in the News Solventum completed the $4 billion divestiture of its Purification & Filtration business to Thermo Fisher, using most of the $3.4 billion net proceeds to reduce debt and strengthen the balance sheet while raising FY25 organic sales growth, adjusted EPS, free cash flow, and operating margin guidance.
User avatar
새로운 내러티브 • Mar 30

New VAC Product And AI Will Simplify Procedures

Streamlining operations and divesting non-core assets are expected to improve margins, reduce leverage, and focus growth efforts on core segments.
Seeking Alpha • Feb 26

Solventum: An Impressive Sale Of Purification And Filtration

Summary Solventum's impressive $4.1 billion divestment to Thermo Fisher significantly reduces debt, enhancing its financial stability and potentially boosting earnings per share. The strategic sale has made me more optimistic about Solventum's future, maintaining a modest long position. The company's valuation remains attractive, with earnings multiples reasonable, especially considering the substantial deleveraging progress. Solventum still needs to achieve solid organic growth, but the recent positive developments justify continued investment. Read the full article on Seeking Alpha
Seeking Alpha • Nov 30

Solventum: Concerns After A Partial Re-Rating

Summary Solventum's sales and margins have shown modest improvement, but concerns about 2025 earnings due to non-quantified headwinds make me cautious at current levels. The company, spun off from 3M, has a diversified healthcare portfolio but has faced flattish sales and high debt, impacting its valuation. Despite recent stock gains and improved guidance, potential 2025 earnings pressure from costs and investments warrants a cautious approach, prompting me to trim my position. Solventum's exploration of selling its purification filtration business could be a potential catalyst, but the impact remains uncertain without indicative pricing. Read the full article on Seeking Alpha
Seeking Alpha • Sep 11

Solventum: No Rush To Buy As Post-Spin Execution Will Take Time To Play Out

Summary 3M's healthcare spinoff, Solventum (SOLV), has seen its share price decline by 15% since the event in April, even as its parent has moved up steadily by 26%. SOLV could lose market share, with management projecting only 0.5% growth for FY24 and consensus expecting a similar cadence of revenue growth next year, well below the 4-6% industry growth. Solventum's financial health is strained by a high debt load and potentially lower threshold of FCF generation, dampening any near-term prospects of a dividend. Despite a compelling forward P/E ratio, investors should note that SOLV's earnings growth will be weighed down by a higher cost base as a standalone entity. SOLV's stock has benefitted from decent momentum since mid-July, but conditions are now looking overbought. Read the full article on Seeking Alpha
Seeking Alpha • Jul 07

Solventum: Stumbling Out Of The Gate

Summary Solventum Corporation, a spinoff of 3M Company's healthcare business, has seen an over 40% decline in shareholder value since going public in late March. The company is now reportedly considering acquiring Mediwound, a provider of tissue repair solutions, which may change its growth prospects. The stock appears attractive on a P/E and free cash flow yield basis, but that view comes with a couple of caveats. An analysis around Solventum Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • May 17

Solventum: A Reasonable Start, Still Some Questions To Be Asked

Summary Solventum Corporation, a healthcare spin-off from 3M Company, had a soft start of trading due to flattish sales and high debt. The company operates in various healthcare segments, including MedSurg, dental solutions, and purification & filtration activities. Despite concerns, Solventum posted positive first-quarter earnings, with sales slightly increasing and margin gains. These earnings likely cannot be sustained, although debt reduction (as a priority) is promising. Read the full article on Seeking Alpha

이익 및 매출 성장 예측

NYSE:SOLV - 애널리스트 향후 추정치 및 과거 재무 데이터 (USD Millions)
날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수
12/31/20288,7957888061,28610
12/31/20278,4766406941,08712
12/31/20268,19339120860012
3/31/20268,2621,432-203151N/A
12/31/20258,3251,556-10369N/A
9/30/20258,4021,52450493N/A
6/30/20258,388380147586N/A
3/31/20258,308379385772N/A
12/31/20248,2544798051,185N/A
9/30/20248,2157201,1721,513N/A
6/30/20248,2071,0581,5231,837N/A
3/31/20248,2021,2901,5211,848N/A
12/31/20238,1971,3461,6251,915N/A
9/30/20238,1661,3811,5301,814N/A
6/30/20238,1011,2561,5421,817N/A
3/31/20238,0831,2861,5601,820N/A
12/31/20228,1301,3431,4281,679N/A
12/31/20218,1711,4601,9252,202N/A
12/31/20207,2811,1381,7552,026N/A

애널리스트 향후 성장 전망

수입 대 저축률: SOLV 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -5.3%).

수익 vs 시장: SOLV 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -5.3%).

고성장 수익: SOLV 의 수익은 향후 3년간 감소할 것으로 예상됩니다.

수익 대 시장: SOLV 의 수익(연간 2.7%)이 US 시장(연간 11.8%)보다 느리게 성장할 것으로 예상됩니다.

고성장 매출: SOLV 의 수익(연간 2.7%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.

주당순이익 성장 예측

향후 자기자본이익률

미래 ROE: SOLV의 자본 수익률은 3년 후 25.8%로 높을 것으로 예상됩니다.

성장 기업 찾아보기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/05/27 01:57
종가2026/05/27 00:00
수익2026/03/31
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Solventum Corporation는 20명의 분석가가 다루고 있습니다. 이 중 13명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Travis SteedBofA Global Research
Travis SteedBofA Global Research
Michael GormanBTIG